ENTX
NASDAQEntera Bio Ltd.
Price$2.69+0.02 (+0.56%)
01:30 PM07:45 PM
News · 26 weeks57+60%
2026-04-192026-10-11
Mix3790d
- SEC Filings12(32%)
- Insider10(27%)
- Other9(24%)
- Analyst3(8%)
- Leadership2(5%)
- Offering1(3%)
Latest news
25 items- SECSEC Form DEF 14A filed by Entera Bio Ltd.DEF 14A - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual MeetingPost-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia) These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced data from a Plenary Poster Presentation (abstract #7062) and a Late-breaking Poster Presentation (abstract #872
- PREntera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual MeetingTEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. The additional presentation, titled "EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design," has been
- SECSEC Form 8-K filed by Entera Bio Ltd.8-K - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial ExpertiseTEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board. "I am delighted to welcome Laura to our Board as Entera enters an important new chapter of late-stage clinical execution, commercial preparedness for EB613 and advancement of our broader pipeline," sai
- ANALYSTGuggenheim initiated coverage on Entera Bio with a new price targetGuggenheim initiated coverage of Entera Bio with a rating of Buy and set a new price target of $11.00
- SECSEC Form PRE 14A filed by Entera Bio Ltd.PRE 14A - Entera Bio Ltd. (0001638097) (Filer)
- ANALYSTCantor Fitzgerald initiated coverage on Entera BioCantor Fitzgerald initiated coverage of Entera Bio with a rating of Overweight
- ANALYSTLeerink Partners initiated coverage on Entera Bio with a new price targetLeerink Partners initiated coverage of Entera Bio with a rating of Outperform and set a new price target of $9.00
- SECSEC Form EFFECT filed by Entera Bio Ltd.EFFECT - Entera Bio Ltd. (0001638097) (Filer)
- SECSEC Form 424B3 filed by Entera Bio Ltd.424B3 - Entera Bio Ltd. (0001638097) (Filer)
- PRCorrection: Entera to Participate in Upcoming Fall Investor ConferencesTEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare ConferenceFireside Chat: September 10, 2026 at 1:00 p.m. Eastern Time, Waldorf Astoria New York, 301 Park Avenue, New York, NY Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceNovember 9, 2026, Fireside Chat and 1x1 Meetings, Location: Boston, MA Evercore ISI 9th Annual Healthcare ConferenceNovember 30–December 2, 2026, in person, Locati
- PREntera to Participate in Upcoming Fall Investor ConferencesTEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare ConferenceFireside Chat: September 10, 2026 at 1:00 p.m. Eastern Time, Waldorf Astoria New York, 301 Park Avenue, New York, NY 2026 Leerink Partners Biopharma SummitSeptember 23–25, 2026, in person, Location: Healdsburg, CA Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceNovember 9, 2026, Fireside Chat and 1x1 Meetings, Location: Boston
- SECSEC Form S-3 filed by Entera Bio Ltd.S-3 - Entera Bio Ltd. (0001638097) (Filer)
- INSIDERSEC Form 3 filed by new insider Camisasca Riccardo Paolo3 - Entera Bio Ltd. (0001638097) (Issuer)
- SECEntera Bio Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 InitiationDr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens Entera’s clinical execution team and late-stage development capabilities ahead of planned EB613 Phase 3 initiation TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced the appointment of Riccardo Paolo Camisasca, M.D., as Chief Medical Officer. Dr. Camisasca is a physician, clinical pharmacologist and global pharmaceutical executive with more than 30 years of experience spa
- SECSEC Form D filed by Entera Bio Ltd.D - Entera Bio Ltd. (0001638097) (Filer)
- INSIDERDirector Rubin Steven D was granted 19,117 units of Ordinary Shares, increasing direct ownership by 127% to 34,117 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Malca Yonatan was granted 22,815 units of Ordinary Shares, increasing direct ownership by 29% to 100,231 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Taitel Haya was granted 20,790 units of Ordinary Shares, increasing direct ownership by 21% to 119,269 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Ellis Sean was granted 20,034 units of Ordinary Shares, increasing direct ownership by 11% to 208,132 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Yaacov-Garbeli Dana4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Galitzer Hillel4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERSEC Form 4 filed by Chief of R&D Burshtein Gregory4 - Entera Bio Ltd. (0001638097) (Issuer)
ENTX FAQ
7 questionsWhat does Entera Bio Ltd. do?
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc...Where does ENTX stock trade?
Entera Bio Ltd. (ENTX) is listed on NASDAQ.What sector and industry is ENTX in?
Entera Bio Ltd. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Entera Bio Ltd. go public?
Entera Bio Ltd. (ENTX) completed its IPO in 2018.What are analysts saying about ENTX?
Entera Bio Ltd. has had 3 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $1100.00 price target on 2026-09-25. Recent price targets range from $900.00 to $1100.00.What companies are similar to ENTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ENTX side-by-side with any of them on Quantisnow.How can I track ENTX on Quantisnow?
Quantisnow aggregates Entera Bio Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENTX to receive live email and push alerts on every new disclosure.